HealthcareHealthcare ServicesHealthcare Service Provider

Transgene Biotek Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 34 filings·Updated 11 Aug 2026
Showing 10 of 34 filings.
11 Aug 20261 filing
Company UpdateNewspaper Publication

Newspaper Publication

Filed 12:52View Source
7 Aug 20261 filing
Board MeetingOutcome of Board Meeting

Transgene Biotek Board approves Q1 2026-27 unaudited results, AGM extension, and internal auditors.

Key board decisions

  • Unaudited standalone and consolidated results for quarter ended 30 June 2026 approved.
  • Limited Review Report (standalone & consolidated) for quarter ended 30 June 2026 approved.
  • AGM extension for FY2025-26 approved, subject to ROC approval.
  • Appointed M/s Manisha Dubey & Associates as Internal Auditors for FY2026-27.
  • Regulatory disclosure under Regulation 30: internal auditor appointment details provided.
  • Auditor note: consolidated quarterly results not reviewed.
  • SAT matter adjourned to 17 August 2026.
  • ED order hearing started; adjourned to 10 September 2026.
  • NCLT matter adjourned to 23 September 2026.
  • Nitin Didwania: order dated 8 July; appeal filed.
  • BIRAC: no communication since 14 November 2025.
  • Customs & Excise: no new development.
Filed 11:42View Source
13 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Regulation 74(5) certificate confirms dematerialisation processing, listing, and cancellation actions

Dematerialisation status

  • Dematerialisation requests processed; RTA confirmed accepted/rejected to depositories for the quarter.
  • Securities dematerialised have been listed on the stock exchange where earlier issues are listed.
  • Physical certificates for dematerialisation were mutilated and cancelled; depository name substituted as registered owner within the prescribed timeline.
Filed 19:28View Source
29 May 20261 filing
Board MeetingOutcome of Board Meeting

Transgene Biotek Ltd - 526139 - Board Meeting Outcome for Outcome Of Board Meeting And Submission Of Audited Financial Results For The Fourth Quarter And Financial Year Ended March 31, 2026

Financial results

  • Board approved audited standalone and consolidated results for Q4 and FY ended 31 March 2026.
  • Standalone and consolidated auditors issued unmodified opinions on the audited results.

Key performance

  • Standalone FY 2025-26 profit before tax was a loss of ₹165.29 lakh.
  • Consolidated FY 2025-26 profit before tax was a loss of ₹165.29 lakh.
  • Standalone and consolidated basic EPS for FY 2025-26 was negative ₹0.22 per share.

Other statements approved

  • Board approved audited standalone and consolidated cash flow statements for FY 2025-26.
  • Board approved standalone and consolidated balance sheets and related notes.

Regulatory and legal matters

  • Company disclosed ongoing appeals before SAT, ED Tribunal, and NCLT with future hearing dates.
  • Company reported no further development in customs and excise matters.
  • Company reported no further communication from BIRAC since 14 November 2025.
Filed 11:35View Source
15 May 20261 filing
Board Meeting

Transgene Biotek Ltd - 526139 - Board Meeting Intimation for Intimation Of The Board Meeting Of The Company - This Is To Inform You That A Meeting Of Board Of Directors Of The Company Will Be Held On Friday 29Th May 2026.

Meeting Details

  • Board meeting scheduled for Friday, 29 May 2026.

Key Agenda Items

  • Approve audited standalone and consolidated financial results for Q4 and year ended 31 March 2026.
Filed 09:25View Source
13 Apr 20265 filings
OthersFormat of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....

Filed 18:06View Source
Company UpdateReg. 32 (1), (3) - Statement of Deviation & Variation

Non-Applicability of Regulation 32(1) of SEBI.

Filed 18:01View Source
Others57 (4) : Prior intimation to the beginning of the quarter

Compliance - 57 (4)

Filed 17:59View Source
Others57 (5) : intimation after the end of quarter

Non-Applicability of Reg -57 (5) of SEBI LODR Regulations, 2015.

Filed 17:57View Source
Company UpdateReg. 7(3) – Compliance Certificate (RTA & Compliance Officer)

Compliance certificate 7(3)

Filed 17:54View Source
Showing 10 of 34 filings